A&O Shearman advises Boston Scientific on its strategic investment in MiRus

As part of the agreement, Boston Scientific has also secured an exclusive option to acquire MiRus’ transcatheter aortic valve replacement (TAVR) system, subject to additional aggregate cash payments of USD3bn and the completion of certain milestones. This investment supports Boston Scientific’s continued expansion in its cardiovascular portfolio and adoption of innovative technologies.

Boston Scientific is a global medical technology company that develops devices and therapies used by physicians to diagnose and treat complex cardiovascular, respiratory, digestive, oncological, neurological, and urological conditions. With more than 45 years in the sector, the company focuses on advancing science to meet unmet patient needs and improve healthcare value.

MiRus develops and commercializes proprietary biomaterials, implants, and procedural solutions for the treatment of cardiovascular and orthopedic diseases. MiRus’ lead platform, the SIEGEL™ balloon-expandable TAVR system, is an investigational device designed to treat severe aortic stenosis with a minimally invasive valve replacement solution.

The A&O Shearman team was led by M&A partners Clare O’Brien and Derrick Lott, with key support from counsel Andreas Piepers, and associate William Kim. The team also included partners John Cannon, Melisa Brower, JB Betker, John Hibbard, Larry Crouch, Richard Alsop, and Erika Kent and associates Alexandra Kasper, Austin Grossfeld, and Michael Buiteweg.